On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Stocktwits on MSN3d
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz StrongShares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback